视网膜中央静脉阻塞继发顽固性黄斑水肿4年预后1例
A Case Report of 4-Year Outcomes of Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion
摘要: 视网膜中央静脉阻塞(CRVO)是常见的视网膜血管疾病，黄斑水肿(ME)是CRVO患者视功能损害最常见的原因。ME的治疗方法包括激光光凝、抗血管内皮细胞生长因子(VEGF)药物、皮质类固醇激素等，尽管不同的治疗方式已被证明对改善黄斑水肿有效，但许多CRVO患者经过短期治疗后，仍有持续或复发的ME。然而，关于RVO长期预后结果的研究较少。本案例旨在提供1例CRVO-ME长期的治疗预后，探讨CRVO-ME的病程、长期管理及治疗策略。
Abstract: Central retinal vein occlusion (CRVO) is a common retinal vascular disease. Macular edema (ME) is the most frequent cause of the visual impairments in eyes with CRVO. ME treatment modalities include LASER therapy, and intravitreal therapy with anti-vascular endothelial growth factor (VEGF) agents or corticosteroids. Although different treatment modalities have been shown to be effective in improving ME, many patients with CRVO have persistent or recurrent ME despite short-term treatment. However, there is very limited long-term data for outcomes of treatment for RVO. The aim of this case report is to provide long-term outcomes in patients with ME secondary to CRVO after therapy, investigate the course, long-term management and treatment strategies of ME secondary to CRVO.
文章引用：陈瑞红, 王玲. 视网膜中央静脉阻塞继发顽固性黄斑水肿4年预后1例[J]. 临床医学进展, 2021, 11(6): 2762-2767. https://doi.org/10.12677/ACM.2021.116400

参考文献

[1] Campochiaro, P.A., Sophie, R., Pearlman, J., et al. (2014) Long-Term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study. Ophthalmology, 121, 209-219. [Google Scholar] [CrossRef] [PubMed]
[2] Chatziralli, I., Theodossiadis, G., Chatzirallis, A., et al. (2018) Ranibizumab for Retinal Vein Occlusion: Predictive Factors and Long-Term Outcomes in Real-Life Data. Retina, 38, 559-568. [Google Scholar] [CrossRef] 
[3] Spooner, K., Fraser-Bell, S., Hong, T., et al. (2019) Five-Year Outcomes of Retinal Vein Occlusion Treated with Vascular Endothelial Growth Factor Inhibitors. BMJ Open Opthalmology, 4, e000249. [Google Scholar] [CrossRef] [PubMed]
[4] Singer, M., Tan, C.S., Bell, D., et al. (2014) Area of Peripheral Retinal Nonperfusion and Treatment Response in Branch and Central Retinal Vein Occlusion. Retina, 34, 1736-1742. [Google Scholar] [CrossRef] 
[5] Nourinia, R., Emamverdi, M., Ramezani, A., et al. (2020) Peripheral Ishchemic Retinal Photocoagulation in Addition to Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Double Masked Controlled Clinical Trial. Retina, 40, 1110-1117. [Google Scholar] [CrossRef] 
[6] Wykoff, C.C., Ou, W.C., Wang, R., et al. (2017) Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology, 124, 919-921. [Google Scholar] [CrossRef] [PubMed]
[7] Campochiaro, P.A., Hafiz, G., Mir, T.A., et al. (2015) Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. Ophthalmology, 122, 1426-1437. [Google Scholar] [CrossRef] [PubMed]
[8] Tadayoni, R., Waldstein, S.M., Boscia, F., et al. (2017) Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology, 124, 1778-1787. [Google Scholar] [CrossRef] [PubMed]
[9] Schmidt-Erfurth, U., Garcia-Arumi, J., Gerendas, B.S., et al. (2019) Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 242, 123-162. [Google Scholar] [CrossRef] [PubMed]
[10] Osaka, R., Muraoka, Y., Nakano, Y., et al. (2020) One-Year Results of Anti-Vascular Endothelial Growth Factor Therapy Combined with Triamcinolone Acetonide for Macular Edema Associated with Branch Retinal Vein Occlusion. Japanese Journal of Ophthalmology, 64, 605-612. [Google Scholar] [CrossRef] [PubMed]
[11] Moon, J., Kim, M. and Sagong, M. (2016) Combination Therapy of Intravitreal Bevacizumab with Single Simultaneous Posterior Subtenon Triamcinolone Acetonide for Macular Edema Due to Branch Retinal Vein Occlusion. Eye (Lond), 30, 1084-1090. [Google Scholar] [CrossRef] [PubMed]

为你推荐